A recent study published in Nucleic Acids Research has unveiled the crucial role of the protein TDP43 in regulating genes that are essential for DNA repair. Researchers found that both insufficient and excessive levels of TDP43 can lead to an overactivation of these repair genes, which instead of safeguarding cells, may endanger neurons and destabilize the genome, potentially heightening the risk of cancer.
The Importance of TDP43 in DNA Repair Mechanisms
Dr. Muralidhar L. Hegde, the lead investigator and a professor at the Houston Methodist Research Institute's Center for Neuroregeneration, emphasized the fundamental nature of DNA repair in biological processes. "Our findings reveal that TDP43 is not merely another RNA-binding protein involved in splicing; it is a vital regulator of the mismatch repair machinery. This discovery has significant implications for conditions such as ALS and frontotemporal dementia (FTD), where TDP43 function is compromised," he stated.
The research team also identified a connection between TDP43 and cancer. By scrutinizing extensive cancer databases, they observed that elevated levels of TDP43 correlate with a higher mutation count in tumors.
Connecting Neurodegeneration and Cancer through TDP43
"Our results indicate that the biological significance of this protein extends beyond ALS and FTD," Dr. Hegde explained. "In various cancers, TDP43 appears to be upregulated, associating it with an increased mutation burden. This positions it at the crossroads of two critical health challenges of our era: neurodegeneration and cancer."
The implications of this research could pave the way for innovative treatment strategies. Preliminary laboratory models demonstrated that mitigating the excessive DNA repair activity linked to abnormal TDP43 could partially reverse cellular damage. Dr. Hegde suggested that managing DNA mismatch repair might provide a promising therapeutic avenue.
The study included contributions from a diverse team of researchers, including Vincent Provasek, Suganya Rangaswamy, and others from Houston Methodist, as well as experts from MD Anderson Cancer Center, University of Massachusetts, UT Southwestern Medical Center, and Binghamton University.
This research received significant support from the National Institute of Neurological Disorders and Stroke (NINDS), the National Institute on Aging of the National Institutes of Health (NIH), the Sherman Foundation Parkinson's Disease Research Challenge Fund, and internal funding from the Houston Methodist Research Institute.